Quotient (QTNT) Upgraded to “Hold” by BidaskClub

BidaskClub upgraded shares of Quotient (NASDAQ:QTNT) from a sell rating to a hold rating in a research note released on Tuesday morning.

QTNT has been the subject of several other reports. ValuEngine upgraded shares of Quotient from a hold rating to a buy rating in a research report on Tuesday, August 28th. Zacks Investment Research upgraded shares of Quotient from a sell rating to a hold rating in a research report on Wednesday, October 10th.

Shares of QTNT stock opened at $6.75 on Tuesday. Quotient has a 52 week low of $2.78 and a 52 week high of $9.02.

Quotient (NASDAQ:QTNT) last announced its quarterly earnings results on Monday, November 5th. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.17). The firm had revenue of $6.25 million for the quarter, compared to analysts’ expectations of $5.80 million. On average, equities analysts expect that Quotient will post -1.92 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently made changes to their positions in QTNT. Trexquant Investment LP bought a new stake in Quotient during the second quarter valued at approximately $102,000. PEAK6 Investments LLC bought a new stake in Quotient during the third quarter valued at approximately $109,000. West Chester Capital Advisors Inc. bought a new stake in Quotient during the second quarter valued at approximately $120,000. Bank of America Corp DE grew its position in Quotient by 539.0% during the second quarter. Bank of America Corp DE now owns 16,768 shares of the company’s stock valued at $135,000 after buying an additional 14,144 shares during the period. Finally, Cim Investment Mangement Inc. bought a new stake in Quotient during the second quarter valued at approximately $407,000. Institutional investors own 53.75% of the company’s stock.

About Quotient

Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening.

Read More: Understanding Relative Strength Index

Receive News & Ratings for Quotient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply